Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT ID: NCT01101984
Last Updated: 2012-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
400 participants
INTERVENTIONAL
2010-02-28
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DE-089
DE-089 ophthalmic solution
diquafosol ophthalmic solution
DE-089 topical ocular application, 6 times daily for 4 weeks.
0.1% sodium hyaluronate ophthalmic solution.
0.1% HA topical ocular application, 6 times daily for 4 weeks.
HA
0.1% sodium hyaluronate ophthalmic solution
0.1% sodium hyaluronate ophthalmic solution.
0.1% HA topical ocular application, 6 times daily for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diquafosol ophthalmic solution
DE-089 topical ocular application, 6 times daily for 4 weeks.
0.1% sodium hyaluronate ophthalmic solution.
0.1% HA topical ocular application, 6 times daily for 4 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Keratoconjunctival disorder confirmed with vital dye staining
* Abnormal Schirmer score results
Exclusion Criteria
* Those who need to wear contact lenses during the clinical study
21 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Santen Pharmaceutical Co., Ltd.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eye & Ear Hospital of Fudan University
Shanghai, , China
Singapore Eye Research Institute
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gong L, Sun X, Ma Z, Wang Q, Xu X, Chen X, Shao Y, Yao K, Tang L, Gu Y, Yuan H, Chua WH, Chuan JC, Tong L. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol. 2015 Jul;99(7):903-8. doi: 10.1136/bjophthalmol-2014-306084. Epub 2015 Jan 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
08901
Identifier Type: -
Identifier Source: org_study_id